BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21095237)

  • 1. PGE1 and PGE2 modify platelet function through different prostanoid receptors.
    Iyú D; Jüttner M; Glenn JR; White AE; Johnson AJ; Fox SC; Heptinstall S
    Prostaglandins Other Lipid Mediat; 2011 Feb; 94(1-2):9-16. PubMed ID: 21095237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PGE(2) reverses G(s)-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-G(s)-mediated inhibition of platelet aggregation by interaction with EP4 receptors.
    Glenn JR; White AE; Iyu D; Heptinstall S
    Platelets; 2012; 23(5):344-51. PubMed ID: 22436052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of prostanoid receptors in mediating the effects of PGE(2) on human platelet function.
    Iyú D; Glenn JR; White AE; Johnson AJ; Fox SC; Heptinstall S
    Platelets; 2010; 21(5):329-42. PubMed ID: 20433310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors.
    Petrucci G; De Cristofaro R; Rutella S; Ranelletti FO; Pocaterra D; Lancellotti S; Habib A; Patrono C; Rocca B
    J Pharmacol Exp Ther; 2011 Feb; 336(2):391-402. PubMed ID: 21059804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
    Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
    Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease.
    Heptinstall S; Espinosa DI; Manolopoulos P; Glenn JR; White AE; Johnson A; Dovlatova N; Fox SC; May JA; Hermann D; Magnusson O; Stefansson K; Hartman D; Gurney M
    Platelets; 2008 Dec; 19(8):605-13. PubMed ID: 19012178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of PGE(2) in human atherosclerotic plaque on platelet EP(3) and EP(4) receptor activation and platelet function in whole blood.
    Schober LJ; Khandoga AL; Dwivedi S; Penz SM; Maruyama T; Brandl R; Siess W
    J Thromb Thrombolysis; 2011 Aug; 32(2):158-66. PubMed ID: 21424266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
    Iyú D; Glenn JR; White AE; Fox SC; van Giezen H; Nylander S; Heptinstall S
    Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential regulation of airway smooth muscle cell migration by E-prostanoid receptor subtypes.
    Aso H; Ito S; Mori A; Suganuma N; Morioka M; Takahara N; Kondo M; Hasegawa Y
    Am J Respir Cell Mol Biol; 2013 Mar; 48(3):322-9. PubMed ID: 23221043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reciprocal regulation of human platelet function by endogenous prostanoids and through multiple prostanoid receptors.
    Hubertus K; Mischnik M; Timmer J; Herterich S; Mark R; Moulard M; Walter U; Geiger J
    Eur J Pharmacol; 2014 Oct; 740():15-27. PubMed ID: 25003953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo intra-luteal implants of prostaglandin (PG) E1 or E2 (PGE1, PGE2) prevent luteolysis in cows. II: mRNA for PGF2α, EP1, EP2, EP3 (A-D), EP3A, EP3B, EP3C, EP3D, and EP4 prostanoid receptors in luteal tissue.
    Weems YS; Bridges PJ; Jeoung M; Arreguin-Arevalo JA; Nett TM; Vann RC; Ford SP; Lewis AW; Neuendorff DA; Welsh TH; Randel RD; Weems CW
    Prostaglandins Other Lipid Mediat; 2012 Jan; 97(1-2):60-5. PubMed ID: 22120546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation.
    Philipose S; Konya V; Sreckovic I; Marsche G; Lippe IT; Peskar BA; Heinemann A; Schuligoi R
    Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2416-23. PubMed ID: 21071691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of eosinophils with endothelial cells is modulated by prostaglandin EP4 receptors.
    Konya V; Philipose S; Bálint Z; Olschewski A; Marsche G; Sturm EM; Schicho R; Peskar BA; Schuligoi R; Heinemann A
    Eur J Immunol; 2011 Aug; 41(8):2379-89. PubMed ID: 21681739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation.
    Kuriyama S; Kashiwagi H; Yuhki K; Kojima F; Yamada T; Fujino T; Hara A; Takayama K; Maruyama T; Yoshida A; Narumiya S; Ushikubi F
    Thromb Haemost; 2010 Oct; 104(4):796-803. PubMed ID: 20664890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin E2 levels and platelet function are different in cord blood compared to adults.
    Schlagenhauf A; Haidl H; Leschnik B; Leis HJ; Heinemann A; Muntean W
    Thromb Haemost; 2015 Jan; 113(1):97-106. PubMed ID: 25118631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers.
    Fox SC; May JA; Johnson A; Hermann D; Strieter D; Hartman D; Heptinstall S
    Platelets; 2013; 24(5):392-400. PubMed ID: 22866894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A noble function of BAY 11-7082: Inhibition of platelet aggregation mediated by an elevated cAMP-induced VASP, and decreased ERK2/JNK1 phosphorylations.
    Lee HS; Kim SD; Lee WM; Endale M; Kamruzzaman SM; Oh WJ; Cho JY; Kim SK; Cho HJ; Park HJ; Rhee MH
    Eur J Pharmacol; 2010 Feb; 627(1-3):85-91. PubMed ID: 19913011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor.
    Dovlatova N; Wijeyeratne YD; Fox SC; Manolopoulos P; Johnson AJ; White AE; Latif ML; Ralevic V; Heptinstall S
    Thromb Haemost; 2008 Aug; 100(2):261-70. PubMed ID: 18690346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostaglandin E2 promotes liver cancer cell growth by the upregulation of FUSE-binding protein 1 expression.
    Ma J; Chen M; Xia SK; Shu W; Guo Y; Wang YH; Xu Y; Bai XM; Zhang L; Zhang H; Zhang M; Wang YP; Leng J
    Int J Oncol; 2013 Mar; 42(3):1093-104. PubMed ID: 23338277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opposing effects of prostaglandin E
    Carboneau BA; Allan JA; Townsend SE; Kimple ME; Breyer RM; Gannon M
    Mol Metab; 2017 Jun; 6(6):548-559. PubMed ID: 28580285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.